ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Journal of Clinical Oncology

• Publication date

  2005-12-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2005.02.907PMID 16172458
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Statistical Methods in Medical Research - Editorial

  2005cited by this paper
• ChlVPP/ABVVP, a first line ‘hybrid’ combination chemotherapy for advanced Hodgkin's lymphoma: a retrospective analysis

  2004cited by this paper
• Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial.

  2003cited by this paper
• Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease.

  2003cited by this paper
• Advanced Hodgkin's disease: ABVD is better, yet is not good enough!

  2003influential reference
• Primary systemic treatment of advanced Hodgkin's disease with EVA (etoposide, vinblastine, doxorubicin): 10-year follow-up.

  2003cited by this paper
• Involved-field radiotherapy for advanced Hodgkin's lymphoma.

  2003cited by this paper
• Long-term follow-up of Hodgkin's disease trial.

  2002cited by this paper
• New treatments for advanced Hodgkin's disease: an uphill fight beginning close to the top.

  2002cited by this paper
• Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial.

  2002cited by this paper
• Comparison of chemotherapy to radiotherapy as consolidation of complete or good partial response after six cycles of chemotherapy for patients with advanced Hodgkin's disease: results of the groupe d'études des lymphomes de l'Adulte H89 trial.

  2000cited by this paper
• Lomustine and melphalan cannot be replaced by cyclophosphamide and etoposide without reducing efficacy in MOPPEBVCAD chemotherapy for advanced Hodgkin's disease.

  2000cited by this paper
• Assessment of the stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin's disease: Eastern Cooperative Oncology Group pilot study E1492.

  2000cited by this paper
• Long-term results of an intensive regimen: VEBEP plus involved-field radiotherapy in advanced Hodgkin's disease.

  1999cited by this paper
• MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial.

  1998cited by this paper
• A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease.

  1998cited by this paper
• Long-term results from MOPPEBVCAD chemotherapy with optional limited radiotherapy in advanced Hodgkin's disease.

  1998cited by this paper
• Treatment of advanced Hodgkin's disease with chemotherapy--comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group.

  1997cited by this paper
• Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines.

  1996cited by this paper
• Rationale for dose escalation of first line conventional chemotherapy in advanced Hodgkin's disease. German Hodgkin's Lymphoma Study Group.

  1996cited by this paper
• Further chemotherapy versus low-dose involved-field radiotherapy as consolidation of complete remission after six cycles of alternating chemotherapy in patients with advanced Hodgkin's disease

  1995cited by this paper
• Further chemotherapy versus low-dose involved-field radiotherapy as consolidation of complete remission after six cycles of alternating chemotherapy in patients with advance Hodgkin's disease. German Hodgkins' Study Group (GHSG).

  1995cited by this paper
• Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report.

  1995influential reference
• Second cancer risk following Hodgkin's disease: a 20-year follow-up study.

  1994cited by this paper
• MOPP/EBV/CAD hybrid chemotherapy with or without limited radiotherapy in advanced or unfavorably presenting Hodgkin's disease: a report from the Italian Lymphoma Study Group.

  1993cited by this paper
• Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD.

  1992cited by this paper
• Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting.

  1989influential reference
• Reporting outcomes in Hodgkin's disease and lymphoma.

  1987cited by this paper
• MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease.

  1987cited by this paper
• The chemotherapy of lymphomas: looking back, moving forward--the Richard and Hinda Rosenthal Foundation award lecture.

  1987cited by this paper
• Average relative dose intensity and the impact on design of clinical trials.

  1987cited by this paper
• MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma.

  1985cited by this paper
• Treatment of advanced Hodgkin's disease with chemotherapy and irradiation. Controlled trial of two versus three alternating, potentially non-cross-resistant drug combinations.

  1984cited by this paper
• Rationale for the use of alternating non-cross-resistant chemotherapy.

  1982cited by this paper
• Toxicity and response criteria of the Eastern Cooperative Oncology Group

  1982cited by this paper
• Rationale for the use of alternating non-cross-resistant chemotherapy.

  1982cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper

• Role of Radiotherapy in the Management of Elderly Patients With Lymphoma.

  2025cites this paper
• Harnessing multi-source data for individualized care in Hodgkin Lymphoma.

  2024cites this paper
• The Impact of Bleomycin Deficit on Survival in Hodgkin's Lymphoma Patients: A Retrospective Study.

  2024cites this paper
• Doxorubicin inhibits cholesterol efflux through the miR-33/ABCA1 pathway.

  2023cites this paper
• 卡瑞利珠单抗联合AVD方案一线治疗经典型霍奇金淋巴瘤的有效性和安全性

  2022cites this paper
• Treatment Strategies for Advanced Classical Hodgkin Lymphoma in the Times of Dacarbazine Shortage.

  2022cites this paper
• Advanced-stage Hodgkin lymphoma: have effective therapy and modern imaging changed the significance of bulky disease?

  2021cites this paper
• Efficacies and Toxicities of Seven Chemotherapy Regimens for Advanced Hodgkin Lymphoma

  2021cites this paper
• Tracheo-oesophageal groove Hodgkin’s lymphoma presenting as stridor: a diagnostic challenge

  2021cites this paper
• Patterns of Initial Relapse from a Phase 3 Study of Response-Based Therapy for High-Risk Hodgkin Lymphoma (XXXX): A Report from the Children's Oncology Group.

  2021cites this paper
• Efficacy and safety of front-line treatments for advanced Hodgkin lymphoma: a systematic literature review

  2020cites this paper
• Review: Genetic Alterations of Hodgkine's Lymphoma

  2020influential citation
• The Management of Older Patients with Hodgkin Lymphoma

  2020cites this paper
• Principles of Chemotherapy in Hodgkin Lymphoma

  2020cites this paper
• Hodgkin's lymphoma

  2020cites this paper
• Persistent mediastinal FDG uptake on PET-CT after frontline therapy for Hodgkin lymphoma: biopsy, treat or observe?

  2020cites this paper
• Treatment of Advanced-Stage Hodgkin Lymphoma

  2020cites this paper
• JSH practical guidelines for hematological malignancies, 2018: II. Lymphoma-10. Hodgkin lymphoma (HL)

  2019cites this paper
• Does Interim PET Scan After 2 Cycles of ABVD Predict Outcome in Hodgkin Lymphoma? Real-World Evidence

  2019cites this paper
• Treatment outcomes for Hodgkin lymphoma: First report from the Brazilian Prospective Registry

  2018influential citation
• Hodgkin’s lymphoma

  2018cites this paper
• Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology.

  2018cites this paper
• New agents in relapsed/refractory Hodgkin's lymphoma☆

  2017cites this paper
• Hodgkin Lymphoma Outcome: A Retrospective Study from 3 Tertiary Centers in Saudi Arabia

  2017cites this paper
• ABVD chemotherapy with reduced radiation therapy rates in children, adolescents and young adults with all stages of Hodgkin lymphoma

  2017cites this paper
• Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: a systematic review and meta-analysis of randomized clinical trials

  2017cites this paper
• Oncologists’ Perspectives on Consolidation Radiation Treatment after Chemotherapy for Lymphomas: A Survey Study by the Lymphoma Working Committee of the Turkish Oncology Group (TOG)

  2017cites this paper
• Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma.

  2017cites this paper
• An evidence-based review on the value of interim FDG-PET in assessing response to therapy in lymphoma.

  2017cites this paper
• Decreased Prognostic Value of International Prognostic Score in Chinese Advanced Hodgkin Lymphoma Patients Treated in the Contemporary Era

  2016cites this paper
• Trends in Use of Radiation Therapy for Hodgkin Lymphoma From 2000 to 2012 on the Basis of the National Cancer Data Base.

  2016cites this paper
• Treatment of advanced-stage Hodgkin lymphoma.

  2016cites this paper
• Hodgkin lymphoma: an Australian experience of ABVD chemotherapy in the modern era

  2016cites this paper
• Granulocyte colony-stimulating factor in secondary prophylaxis for advanced-stage Hodgkin lymphoma treated with ABVD chemotherapy: a cost-effectiveness analysis

  2016cites this paper
• Controversies on the prognostic value of interim FDG‐PET in advanced‐stage Hodgkin lymphoma

  2016influential citation
• Prognostic value of tumor-associated macrophages in classic Hodgkin ’ s lymphoma : systematic review and meta-analysis

  2016cites this paper
• Clinical features and outcomes of 139 Japanese patients with Hodgkin lymphoma

  2016cites this paper
• Does Radiation Have a Role in Advanced Stage Hodgkin’s or Non-Hodgkin Lymphoma?

  2016cites this paper
• Eight Cycles of ABVD Versus Four Cycles of BEACOPPescalated Plus Four Cycles of BEACOPPbaseline in Stage III to IV, International Prognostic Score ≥ 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial.

  2016cites this paper
• Treatment results in advanced stage Hodgkin's lymphoma: A retrospective study

  2015cites this paper
• XVII. Treatment of advanced‐stage Hodgkin lymphoma

  2015cites this paper
• XVIII. Management of nodular lymphocyte predominant Hodgkin lymphoma

  2015cites this paper
• Recent advances in Hodgkin lymphoma: interim PET and molecular-targeted therapy.

  2015cites this paper
• The GHSG Approach to Treating Hodgkin’s Lymphoma

  2015cites this paper
• Risk- and response-adapted strategies for the management of Hodgkin lymphoma.

  2015cites this paper
• Treatment of Advanced-Stage Hodgkin Lymphoma

  2015cites this paper
• Granulocyte colony-stimulating factor as secondary prophylaxis of febrile neutropenia in the management of advanced-stage Hodgkin lymphoma treated with adriamycin, bleomycin, vinblastine and dacarbazine chemotherapy: a decision analysis

  2014cites this paper
• Hodgkin Disease—An Ever-Evolving Therapy

  2014cites this paper
• Correlation of long non-coding RNA expression with metastasis, drug resistance and clinical outcome in cancer

  2014cites this paper
• Advanced Hodgkin Lymphoma: a New Era of Therapy

  2014cites this paper
• A single institution experience on 314 newly diagnosed advanced Hodgkin lymphoma patients: the role of ABVD in daily practice

  2014cites this paper
• A phase II study of dose‐dense and dose‐intense ABVD (ABVDDD‐DI) without consolidation radiotherapy in patients with advanced Hodgkin lymphoma

  2014cites this paper
• Acute myeloid leukemia: 2013 update on risk‐stratification and management

  2013cites this paper
• Is there a role for consolidation radiotherapy in Hodgkin’s lymphoma in the era of the PET scan?

  2013cites this paper
• Treatment of advanced Hodgkin lymphoma: the more things change, the more they stay the same.

  2013cites this paper
• Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study.

  2013cites this paper
• Hodgkin lymphoma.

  2013cites this paper
• Advanced and relapsed/refractory Hodgkin lymphoma: what has been achieved during the last 50 years.

  2013cites this paper
• Chapitre 14 – Lymphomes : principes thérapeutiques et imagerie post-thérapeutique

  2013cites this paper
• Hematopoietic progenitor cells transplantation for recurrent or refractory Hodgkin's lymphoma

  2013cites this paper
• Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496).

  2013influential citation
• Progress in the initial management of Hodgkin's Lymphoma.

  2013cites this paper
• Lymphome de Hodgkin : traitement de première ligne des stades avancés

  2013cites this paper
• ABVD as the Treatment Option in Advanced Hodgkin’s Lymphoma Patients Older than 45 Years

  2012cites this paper
• Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study.

  2012cites this paper
• Management of children with high‐risk Hodgkin lymphoma

  2012cites this paper
• Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial.

  2012cites this paper
• Tumour burden predicts treatment resistance in patients with early unfavourable or advanced stage Hodgkin lymphoma treated with ABVD and radiotherapy

  2012cites this paper
• Treatment of newly diagnosed advanced stage Hodgkin lymphoma.

  2012cites this paper
• International Prognostic Score in advanced-stage Hodgkin's lymphoma: altered utility in the modern era.

  2012cites this paper
• Hodgkin Lymphoma: From Molecular Pathogenesis to Targeted Therapy

  2012cites this paper
• State of the Art Therapy of Advanced Hodgkin Lymphoma

  2012cites this paper
• State of the art in the treatment of Hodgkin lymphoma

  2012cites this paper
• Single dose palonosetron and dexamethasone in preventing nausea and vomiting induced by high emetogenic ABVD regimen in Hodgkin Lymphoma patients.

  2012cites this paper
• Tumor burden in Hodgkin's lymphoma can be reliably estimated from a few staging parameters.

  2012cites this paper
• Hodgkin lymphoma: 2011 update on diagnosis, risk‐stratification, and management

  2011cites this paper
• Neutropenia and Neutropenic Complications in ABVD Chemotherapy for Hodgkin Lymphoma

  2011influential citation
• Optimal therapy of advanced Hodgkin lymphoma.

  2011cites this paper
• The Management of Classical Hodgkin's Lymphoma: Past, Present, and Future

  2011cites this paper
• Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfomi.

  2011influential citation
• Comparison of chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for patients with early unfavourable or advanced stage Hodgkin lymphoma.

  2011cites this paper
• Therapy of Hodgkin's lymphoma in clinical practice: A retrospective long-term follow-up analysis.

  2011cites this paper
• Chemoresistance as a function of the pretherapy tumor burden and the chemotherapy regimen administered: differences observed with 2 current chemotherapy regimens for advanced Hodgkin lymphoma.

  2011cites this paper
• ESHAP chemotherapy regimen associated to lenalidomide induces complete isotopic remission in Hodgkin’s lymphoma relapsing after autologous stem cell transplantation

  2011cites this paper
• Targetable molecular pathways in classical Hodgkin's lymphoma

  2011cites this paper
• Hodgkin lymphoma.

  2011cites this paper
• 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.

  2011cites this paper
• Treatment of Advanced Hodgkin Lymphoma

  2011cites this paper
• Underreporting of neutropenic toxicity associated with current treatment regimens for selected hematologic malignancies

  2011cites this paper
• Background and Rationale for Radiotherapy in Advanced-Stage Hodgkin Lymphoma

  2011cites this paper
• Lymphome de Hodgkin de l’adulte

  2011cites this paper
• Lymphome de Hodgkin

  2011cites this paper
• The past: what we have learned in the last decade.

  2010cites this paper
• Incidence Patterns and Outcomes for Hodgkin Lymphoma Patients in the United States

  2010cites this paper
• Hodgkin's lymphoma in the young child.

  2010cites this paper
• Role of Radiotherapy in Modern Treatment of Hodgkin's Lymphoma

  2010influential citation
• Consolidation radiotherapy in patients with advanced Hodgkin's lymphoma: survival data from the UKLG LY09 randomized controlled trial (ISRCTN97144519).

  2010cites this paper
• Allogeneic Hematopoietic Stem Cell Transplantation: Does It Have a Place in Treating Hodgkin Lymphoma?

  2010cites this paper
• Hodgkin lymphoma across the age spectrum: epidemiology, therapy, and late effects.

  2010cites this paper
• A decade of progress in lymphoma: advances and continuing challenges.

  2010cites this paper